Genmab

News

Tivdak boosts survival in advanced cervical cancer

Seagen and Genmab's antibody-drug conjugate Tivdak has been shown to improve overall survival when used as a second-line monotherapy for recurrent or metastatic cervical c

News

AbbVie nears EU nod for DLBCL drug epcoritamab

AbbVie and Genmab’s would-be blockbuster epcoritamab has been recommended for conditional approval in the EU as a treatment for diffuse large B-cell lymphoma (DLBCL), an a

News

AbbVie, Genmab eye label expansion for Epkinly

Just a month after AbbVie and Genmab got FDA approval for Epkinly in one form of non-Hodgkin’s lymphoma, the partners are now preparing to file for a second.

News

Chasing AbbVie, Roche gets FDA OK for DLBCL bispecific

Roche has claimed FDA approval for its CD20xCD3 bispecific antibody Columvi as a treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), setting up an

News

CD20 market heats up as FDA OKs AbbVie, Genmab bispecific

AbbVie and partner Genmab have FDA approval for the lead drug in their $3.9 billion cancer

News

ASH: CD20 bispecific antibodies take centre stage in lymphom...

As Roche heads towards an FDA verdict on its CD20xCD3 bispecific Lunsumio for lymphoma before the end of this year, rivals from Regeneron and AbbVie are starting to nip at its heels, with n

Tivdak boosts survival in advanced cervical cancer

AbbVie nears EU nod for DLBCL drug epcoritamab

AbbVie, Genmab eye label expansion for Epkinly

Chasing AbbVie, Roche gets FDA OK for DLBCL bispecific

CD20 market heats up as FDA OKs AbbVie, Genmab bispecific

ASH: CD20 bispecific antibodies take centre stage in lymphom...

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Genmab

Editor's Picks